Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Open excision of the anterior process of the calcaneus for degan classification type II fracture non-union: A retrospective analysis of patient-reported outcomes.

Foot (Edinburgh, Scotland)·2026
Same author

"I am so grateful you made me do this": Navigating AYA-Caregiver Discordance on Shared Decision-making about Fertility Preservation.

Journal of pediatric and adolescent gynecology·2025
Same author

Ethnic differences in skinfold thickness trajectories in children in the born in bradford 1000 cohort study provide modest support for the adipose tissue compartment hypothesis.

Diabetes & metabolic syndrome·2025
Same author

Supplementary inspired oxygen fraction is a simple clinical tool that predicts clinical deterioration.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2025
Same author

COLOFIT: Development and Internal-External Validation of Models Using Age, Sex, Faecal Immunochemical and Blood Tests to Optimise Diagnosis of Colorectal Cancer in Symptomatic Patients.

Alimentary pharmacology & therapeutics·2025
Same author

Pulse oximetry has limited utility in identifying potential patients for long-term oxygen therapy.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2024
Same journal

Comparison of tacrolimus and cyclosporin A in CYP3A5 expressing Chinese de novo kidney transplant recipients: a 2-year prospective study.

International journal of clinical practice. Supplement·2015
Same journal

Efficacy and safety of basiliximab in liver transplantation for patients with hepatitis B virus-related diseases: a single centre study.

International journal of clinical practice. Supplement·2015
Same journal

Human parvovirus B19 infection induced pure red cell aplasia in liver transplant recipients.

International journal of clinical practice. Supplement·2015
Same journal

Interleukin-2 receptor antagonist compared with antithymocyte globulin induction therapy in kidney transplantation from donors after cardiac death.

International journal of clinical practice. Supplement·2015
Same journal

Effect of CYP3A5 polymorphism on the pharmacokinetics of tacrolimus and acute rejection in renal transplant recipients: experience at a single centre.

International journal of clinical practice. Supplement·2015
Same journal

Outcomes of standard dose EC-MPS with low exposure to CsA in DCD renal transplantation recipients with DGF.

International journal of clinical practice. Supplement·2015
See all related articles

Related Experiment Video

Updated: Jun 5, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

Microarray studies in pulmonary arterial hypertension.

S Menon1, J Fessel, J West

  • 1Pulmonary Vascular Research Institute, Jawaharlal Nehru University, New Delhi, India.

International Journal of Clinical Practice. Supplement
|December 24, 2010
PubMed
Summary
This summary is machine-generated.

Microarray studies reveal that end-stage pulmonary arterial hypertension (PAH) involves significant inflammation and altered gene pathways, not just specific gene mutations. Understanding these complex pathways is key to future research.

More Related Videos

Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice
10:20

Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice

Published on: January 16, 2013

Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension
09:40

Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension

Published on: April 11, 2016

Related Experiment Videos

Last Updated: Jun 5, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice
10:20

Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice

Published on: January 16, 2013

Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension
09:40

Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension

Published on: April 11, 2016

Area of Science:

  • Pulmonary Hypertension Research
  • Molecular Biology
  • Genomics

Background:

  • Previous microarray studies analyzed lung tissue and cells from patients with various forms of pulmonary arterial hypertension (PAH).
  • These studies offered insights into end-stage PAH but limited understanding of disease origins.

Purpose of the Study:

  • To synthesize findings from microarray studies on pulmonary arterial hypertension (PAH).
  • To identify key molecular and cellular characteristics of end-stage PAH.
  • To highlight limitations and future directions for PAH research.

Main Methods:

  • Analysis of gene expression data from microarray studies.
  • Comparison of data across different forms of pulmonary arterial hypertension (PAH): idiopathic, hereditary, and secondary.
  • Identification of commonly altered biological pathways and cellular processes.

Main Results:

  • End-stage PAH is characterized by a substantial inflammatory response and induction of angiogenesis-related genes.
  • Suppression of the Bone Morphogenetic Protein (BMP) pathway is observed across idiopathic, hereditary, and secondary PAH.
  • Significant changes in mitochondrial organization and actin dynamics were noted.
  • Pathway-level alterations are more consistent than specific gene changes, suggesting pathway importance.

Conclusions:

  • Specific gene mutations are less critical than the affected biological pathways in achieving physiological endpoints in PAH.
  • Further interpretation of existing microarray data is needed, considering methodological inconsistencies.
  • Identifying critical nodes within these pathways may be crucial for understanding PAH pathogenesis.